The American Quarter Horse Association (AQHA) has released its updated 2025 Drug Rule & Medication Guidelines, offering crucial clarity for owners, trainers, and exhibitors about the responsible use of substances in competition horses. This guide outlines permitted practices, medication thresholds, withdrawal times, and consequences for violations—all aimed at ensuring fairness, animal welfare, and integrity in AQHA-sanctioned events.
A Commitment to Equine Welfare & Fair Competition
AQHA’s approach to medication regulation is rooted in a commitment to protecting the health and well-being of the horse while maintaining the integrity of the sport. The association enforces strict rules that reflect evolving scientific research and industry best practices. The 2025 guide represents both an educational resource and an enforceable rulebook.
Key Highlights from the 2025 Guidelines
-
Therapeutic Medication Use Policy
The AQHA allows for the use of therapeutic medications that are prescribed and administered responsibly. However, these must comply with withdrawal times and dosage limits to avoid positive tests during competition.
- Only one nonsteroidal anti-inflammatory drug (NSAID) is permitted in a horse’s system at the time of competition.
- Horses may not be treated with multiple NSAIDs unless the withdrawal times for the secondary NSAID are strictly followed.
-
Permitted Medications & Dosage Thresholds
The guide provides a comprehensive list of commonly used medications (e.g., phenylbutazone, flunixin, dexamethasone) along with permitted thresholds and recommended withdrawal times. For example:
- Phenylbutazone: Max of 2.0 micrograms/mL in plasma/serum; suggested withdrawal of 72 hours.
- Dexamethasone: Max of 0.005 micrograms/mL; withdrawal time varies based on dosage and route of administration.
Each listed medication includes specifics on administration method (oral, IV, IM), which can affect withdrawal time and testing results.
-
Prohibited Substances
Drugs not used for legitimate therapeutic purposes or with no established safe thresholds are strictly prohibited. These include stimulants, depressants, and substances with performance-enhancing or masking effects. Examples:
- Anabolic steroids, tranquilizers, and psychoactive medications are banned.
- Detection of these substances in a horse’s system will trigger penalties.
-
Stacking Rule (NSAIDs)
The AQHA prohibits the “stacking” of NSAIDs—administering more than one NSAID concurrently to extend or amplify therapeutic effect. The guide details appropriate waiting periods if a horse has received a second NSAID for any reason before competition.
-
Withdrawal Guidelines
A comprehensive table outlines withdrawal recommendations for a wide range of medications, allowing exhibitors to plan treatments in advance of competition. This helps avoid unintentional violations and ensures the horse’s system is compliant at the time of testing.
-
Special Provisions: Corticosteroids, Tranquilizers, & Muscle Relaxants
The guide goes in depth on medications with sedative or tranquilizing effects, including acepromazine and detomidine. These substances, even if used therapeutically, must be fully cleared from the horse’s system well before competition to avoid positive test results.
Corticosteroids such as triamcinolone and methylprednisolone have strict guidance due to their potential joint-enhancing effects and risk of masking injuries.
-
Penalties for Non-Compliance
Violation of the drug policy can result in:
- Disqualification of the horse
- Loss of titles or prizes
- Fines and potential suspension of the responsible party
Repeat offenses or administration of prohibited substances carry harsher consequences, reinforcing AQHA’s zero-tolerance approach.
-
Emergency Use & Reporting
In the case of emergency veterinary treatment close to show time, AQHA encourages exhibitors to file a Medication Report Form before competition. This provides transparency and may offer leniency in specific circumstances, provided the medication is therapeutic and properly documented.
Why This Matters
As drug testing becomes more advanced and precise, it’s essential for those in the industry to stay informed. Even accidental violations can carry severe penalties. The 2025 AQHA Drug Rule & Medication Guidelines empower horse owners and professionals to make responsible, informed decisions while preserving fairness in the show pen.
References
Natashya V.
Founder, StallionCompare.com | Creative Director
Natashya, the founder of StallionCompare.com, is a dynamic force in both the equine and creative industries. As a lifelong equestrian, Natashya’s journey with horses began with Quarter Horses in her hometown in British Columbia, Canada. During her college years she took a brief (and eye opening) hiatus from Quarter Horses to work in the Thoroughbred industry – returning to the AQHA circuit as a young adult. Natashya was also able to reconnect with the quarter horse industry through design. She worked with former owners of Pleasurehorse.com and Show Horse Today on their design needs prior to Robyn Duplisea purchasing the business. Natashya also worked at Horse Canada (HPG) as the Creative Director for many monthly, quarterly, and annual equine magazines. Her passion (read: obsession) for breeding, genetics, and equine pedigrees ran ever-increasingly deep, which lead her to create StallionCompare.com.
Beyond her equine pursuits, Natashya is the Creative Director & Co-Founder of a leading design agency known for its boutique, customer-focused approach. With her expertise, she blends creativity and technology to make a lasting impact in both horse breeding and design.
Latest Articles
